• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Europe Gastrointestinal Drugs Market Share

    ID: MRFR/Pharma/0165-HCR
    85 Pages
    Kinjoll Dey
    October 2025

    Europe, Middle East and Africa Gastrointestinal Drugs Market Research Report, by Drug Category (Acid Neutralizers, Laxatives and Antidiarrheal, Anti-inflammatory drugs), By Route of Administration (Oral, Parenteral, Rectal), By Disease Type (Gastroesophageal Reflux Disease, Inflammatory Bowel Disease), by end user (Hospital Pharmacies, Retail Pharmacies) - Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Europe Gastrointestinal Drugs Market Infographic
    Purchase Options

    Market Share

    Europe Gastrointestinal Drugs Market Share Analysis

    The market for gastrointestinal medications in Europe, the Middle East, and Africa (EMEA) is a vibrant and varied industry that serves a variety of digestive health concerns throughout the three continents. In this crucial area of the pharmaceutical sector, businesses compete for market share by positioning strategies. Market Segmentation: Different parameters, including medicine type, distribution channels, and region, are used to segment the market. Comprehending these categories is essential for businesses seeking to customize their approaches to certain geographic and population demands. Geographic Focus: Businesses frequently use a geocentric strategy, acknowledging the distinctive healthcare environments found in Africa, the Middle East, and Europe. Gaining a competitive edge involves adjusting medicine research, marketing, and distribution methods to the unique features of each location. Disease-Specific Approaches: Due to the wide range of gastrointestinal ailments, businesses frequently concentrate on certain illnesses within this group. For instance, businesses may carve out a niche and take a sizable portion of the market by focusing on common ailments like inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Partnerships and Collaborations: Key to market positioning are strategic alliances with regional research centers, healthcare providers, and pharmaceutical corporations. These kinds of collaborations speed up regulatory clearances, streamline distribution routes, and improve comprehension of local demands. Regulatory Compliance: A sophisticated strategy is required to navigate the regulatory environment in EMEA nations. Profitable businesses place a high priority on regulatory compliance, making sure their medications adhere to the strict guidelines established by regulatory bodies in Europe, the Middle East, and Africa. Patient-Centric Marketing: It's critical to cultivate patient trust and brand loyalty. Businesses spend money on patient-centric marketing techniques that inform and involve customers while enhancing their perception of the business. This strategy works especially well in areas where patient participation in healthcare choices is important. E-commerce and Digital Platforms: The pharmaceutical sector has transformed due to the emergence of e-commerce and digital platforms. Businesses use Internet platforms to sell, market and even provide telemedicine services. This expands their customer base and makes gastrointestinal medications more accessible.

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Leave a Comment

    Market Summary

    The Europe, Middle East and Africa Gastrointestinal Drugs market is projected to grow significantly over the next decade.

    Key Market Trends & Highlights

    Europe, Middle East and Africa Gastrointestinal Drugs Key Trends and Highlights

    • The market valuation is expected to increase from 11.8 USD Billion in 2024 to 23.8 USD Billion by 2035.
    • A compound annual growth rate (CAGR) of 6.58 percent is anticipated from 2025 to 2035.
    • The growth trajectory suggests a robust demand for gastrointestinal drugs across the region.
    • Growing adoption of advanced therapeutic options due to increasing prevalence of gastrointestinal disorders is a major market driver.

    Market Size & Forecast

    2024 Market Size 11.8 (USD Billion)
    2035 Market Size 23.8 (USD Billion)
    CAGR (2025-2035) 6.58%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    AstraZeneca Plc., Johnson & Johnson, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Valeant Pharmaceuticals Inc., Sanofi Ltd., Abbott Laboratories, Allergan Plc, Bayer AG, Janssen Biotech Inc., AbbVie Inc., GlaxoSmithKline Plc., Boehringer Ingelheim GmbH

    Market Trends

    Europe Gastrointestinal Drugs Market Market Drivers

    Market Segment Insights

    Regional Insights

    Key Companies in the Europe Gastrointestinal Drugs Market market include

    Industry Developments

    Market Segmentation

    Report Scope

    Attribute/Metric Details
      Market Size 2032  USD 20.01 Billion
      CAGR   6.0% (2024-2032)
      Base Year   2023
      Forecast Period   2024-2032
      Historical Data   2020
      Forecast Units   Value (USD Billion)
      Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered Drug Category, Route of Administration, Disease Type  and End-user
      Geographies Covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors AstraZeneca Plc.(UK), Johnson & Johnson (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals Inc. (US), Sanofi Ltd. (France), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), AbbVie Inc. (US), Janssen Biotech (US), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany)
      Key Market Opportunities Increasing awareness about the availability of treatment
      Key Market Drivers Increasing prevalence of many gastrointestinal disease

    Market Highlights

    Author

    Kinjoll Dey
    Research Analyst Level I

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    1. DEFINITION
    2. RESEARCH OBJECTIVE
    3. ASSUMPTIONS & LIMITATIONS
    4. ASSUMPTIONS
      1. MARKET STRUCTURE:
    5. RESEARCH METHODOLOGY
      1. RESEARCH PROCESS:
      2. 2.2
      3. PRIMARY RESEARCH
      4. SECONDARY RESEARCH:
    6. MARKET DYNAMICS
      1. DRIVERS
      2. RESTRAINTS
      3. OPPORTUNITIES
      4. MACROECONOMIC INDICATORS
      5. 4
    7. MARKET FACTOR ANALYSIS
      1. PORTERS
      2. FIVE FORCES MODEL
      3. BARGAINING POWER
      4. OF SUPPLIERS
      5. BARGAINING POWER OF BUYERS
      6. THREAT OF NEW ENTRANTS
      7. 4.5
      8. THREAT OF SUBSTITUTES
      9. INTENSITY
      10. OF RIVALRY
    8. EUROPE, MIDDLE EAST
    9. AND AFRICA GASTROINTESTINAL DRUGS MARKET, BY DRUG CATEGORY
      1. 5.1
      2. ACID NEUTRALIZERS
      3. 5.1.2
      4. H2 ANTAGONISTS
      5. DRUGS
    10. ANTACIDS
    11. PROTON PUMP INHIBITORS
    12. OTHERS
      1. LAXATIVES AND ANTIDIARRHEAL
      2. ANTIEMETIC
      3. ANTI-INFLAMMATORY
      4. OTHER
    13. EUROPE,
    14. MIDDLE EAST AND AFRICA GASTROINTESTINAL DRUGS MARKET, BY ROUTE OF ADMINISTRATION
      1. ORAL
      2. PARENTERAL
      3. 6.3
      4. RECTAL
    15. EUROPE, MIDDLE EAST AND AFRICA
      1. GASTROINTESTINAL DRUGS MARKET, DISEASE TYPE
      2. GASTROESOPHAGEAL
      3. REFLUX DISEASE
      4. INFLAMMATORY BOWEL DISEASE
      5. 7.3
      6. OTHER
    16. EUROPE, MIDDLE EAST AND AFRICA GASTROINTESTINAL
    17. DRUGS MARKET
      1. HOSPITAL PHARMACIES
      2. 8.2
      3. RETAIL PHARMACIES
      4. OTHER
      5. 9.
    18. EUROPE, MIDDLE EAST AND AFRICA GASTROINTESTINAL DRUGS MARKET, BY REGION
      1. INTRODUCTION
      2. EUROPE
        1. WESTERN EUROPE
      3. 9.2.1.1
      4. GERMANY
      5. 9.2.1.3
      6. SPAIN
      7. 9.2.1.6
      8. REST OF WESTERN EUROPE
      9. 9.2.2
      10. EASTERN EUROPE
      11. MIDDLE EAST &
      12. AFRICA
    19. COMPETITIVE LANDSCAPE
      1. MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
        1. STRATEGIC PARTNERSHIP
        2. MERGER & ACQUISITION
      2. 11
      3. COMPANY PROFILE
      4. ABBVIE
        1. OVERVIEW
        2. FINANCIALS
        3. KEY DEVELOPMENTS
        4. OVERVIEW
        5. FINANCIALS
        6. KEY DEVELOPMENTS
        7. OVERVIEW
        8. FINANCIALS
        9. STRATEGY
        10. KEY
      5. INC.
      6. 11.1.2
      7. PRODUCT OVERVIEW
      8. 11.2
      9. ASTRAZENECA
      10. 11.2.2
      11. PRODUCT OVERVIEW
      12. 11.3
      13. JOHNSON & JOHNSON
      14. 11.3.2
      15. PRODUCT OVERVIEW
      16. DEVELOPMENT
      17. TAKEDA PHARMACEUTICAL
        1. OVERVIEW
        2. PRODUCT
        3. FINANCIALS
        4. KEY
      18. COMPANY LIMITED
      19. OVERVIEW
      20. DEVELOPMENTS
      21. ALLERGAN PLC
        1. PRODUCT OVERVIEW
        2. FINANCIALS
      22. 11.5.1
      23. OVERVIEW
      24. 11.5.4
      25. KEY DEVELOPMENTS
      26. OTHERS

    Europe, Middle East and Africa Gastrointestinal Drugs Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions